Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

30 Study participants (16.6%) had visceral disease at baseline, with liver or lung disease in 25 participants (13.8%). 81 Study participants (44.8%) had measurable disease at baseline, and 97 (53.6%) ...

Discover a new trial that has evaluated and personalised treatments for metastatic castration-resistant prostate cancer, ...

Adjuvant use of anthracycline–taxane combination therapy is an accepted strategy in the management of high-risk early-stage breast cancer. However, the introduction of this regimen raises the ...

The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...

Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

Throughout any given year, the National Academies convene hundreds of conferences, workshops, symposia, forums, roundtables, and other gatherings that attract the finest minds in academia and the ...

Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

HER2DX has shown a strong association between ERBB2 mRNA and survival in patients with HER2-positive breast cancer.